daclatasvir

an HCV NS5A inhibitor

Also Known As:

BMS-790052; BMS-790052-05; Daklinza; carbamic acid, N,N'-((1,1'-biphenyl)-4,4'-diylbis(1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-dimethyl ester; daclatasvir dihydrochloride

Networked: 589 relevant articles (82 outcomes, 127 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	McPhee, Fiona: 42 articles (01/2019 - 03/2012)
2.	Chayama, Kazuaki: 30 articles (01/2020 - 03/2012)
3.	Kumada, Hiromitsu: 21 articles (01/2020 - 03/2012)
4.	Imamura, Michio: 18 articles (01/2020 - 01/2014)
5.	Noviello, Stephanie: 17 articles (01/2019 - 11/2014)
6.	Kawakami, Yoshiiku: 16 articles (12/2018 - 04/2013)
7.	Aikata, Hiroshi: 14 articles (01/2020 - 01/2014)
8.	Tsuge, Masataka: 14 articles (01/2020 - 01/2014)
9.	Pol, Stanislas: 13 articles (10/2020 - 09/2012)
10.	Ochi, Hidenori: 13 articles (12/2018 - 01/2014)

Related Diseases

1.	Infections 01/01/2016 - "Daclatasvir combined with pegIFN-α/RBV is effective and safe in treating adult patients with CHC, especially HCV genotype 1 infection, and daclatasvir (60 mg/day) is a better choice as compared with daclatasvir (10 mg/day). " 11/01/2023 - "We conducted a phase 3 study to evaluate the efficacy and safety of alfosbuvir in combination with daclatasvir in Chinese patients with HCV infection. " 01/01/2022 - "Here, we evaluate the efficacy and safety of alfosbuvir in combination with daclatasvir in Chinese patients with HCV genotype 1, 2, 3 or 6. In this open-label study, patients with chronic HCV infection were randomly assigned with a 1:1:1 ratio to receive 12 weeks of daclatasvir 60 mg plus alfosbuvir at a dose of 400, 600 or 800 mg (Cohort A, B or C) daily. " 01/01/2022 - "Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study." 10/01/2017 - "A population pharmacokinetic (PPK) model was developed to evaluate effects of covariates on daclatasvir pharmacokinetics in subjects with chronic HCV infection (n = 2149 from 11 studies). "
2.	Hepatitis C 01/01/2017 - "There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. " 12/28/2016 - "Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview." 11/12/2015 - "Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A." 06/01/2015 - "Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C." 01/01/2015 - "The safety of daclatasvir for the treatment of hepatitis C."
3.	Chronic Hepatitis C 07/01/2016 - "Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C." 03/01/2016 - "The aim of this study is to review the efficacy and safety of daclatasvir (DCV)-containing all-oral regimens in clinical studies for chronic hepatitis C treatment. " 01/01/2018 - "Currently, no data are available about the influence of MET on daclatasvir (DCV) plasma levels in patients affected by chronic hepatitis C (CHC). " 01/01/2017 - "A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom. " 10/01/2016 - "The National Institute for Health and Care Excellence (NICE) invited the manufacturer of daclatasvir (Bristol-Myers Squibb) to submit clinical and cost-effectiveness evidence for daclatasvir in combination with other medicinal products within its licensed indication for the treatment of chronic hepatitis C, as part of the Institute's single technology appraisal process. "
4.	Fibrosis (Cirrhosis) 10/01/2016 - "Daclatasvir + sofosbuvir was unlikely to be inferior to comparator treatments in genotype 1 patients; but, due to limited evidence, the relative efficacy of daclatasvir and other treatments in genotype 3 and 4 patients or patients with compensated cirrhosis was uncertain. " 01/01/2019 - "Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program." 01/01/2017 - "ICERs for SOF plus daclatasvir (DCV) regimens versus SoC were over the threshold limit considered, at €56,178/QALY and €77,378/QALY for 'moderate fibrosis' and 'cirrhotic' patients respectively. " 10/01/2016 - "In patients with cirrhosis, daclatasvir-containing regimens were not cost effective. " 05/01/2016 - "Daclatasvir-based protocols are recommended for decompensated cirrhosis, while the Viekera family is recommended in patients with eGFR < 30 ml/min/1.73 sqm, including those on dialysis. "
5.	COVID-19 01/01/2021 - "A physiologically based pharmacokinetic model was generated to estimate daclatasvir's dose and schedule to maximize the probability of success for COVID-19. " 07/01/2021 - "The efficacy of sofosbuvir and daclatasvir as potential choices in treating patients with coronavirus disease 2019 and their recovery can be hypothesized." 01/01/2022 - "This larger trial aimed to assess if the addition of sofosbuvir/daclatasvir to standard care improved clinical outcomes in hospitalized patients with COVID-19. " 01/01/2022 - "The combination of sofosbuvir and daclatasvir has shown preliminary efficacy for hospitalized patients with COVID-19 in four open-label studies with small sample sizes. " 11/01/2020 - "The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19. "

Related Drugs and Biologics

1.	Sofosbuvir
2.	Ribavirin (Virazole)
3.	asunaprevir
4.	Antiviral Agents (Antivirals)
5.	Simeprevir
6.	Interferons
7.	sofosbuvir drug combination ledipasvir
8.	ledipasvir
9.	paritaprevir
10.	grazoprevir

Related Therapies and Procedures

1.	Therapeutics
2.	Liver Transplantation
3.	Renal Dialysis (Hemodialysis)
4.	Retreatment
5.	Oral Administration